期刊文献+
共找到367篇文章
< 1 2 19 >
每页显示 20 50 100
Surgical resection and neoadjuvant therapy in patients with gastric cancer and ovarian metastasis: A real-world study
1
作者 Hui-Ping Yan Hong-Rui Lu +2 位作者 Yu-Xia Zhang Liu Yang Zhe-Ling Chen 《World Journal of Gastrointestinal Surgery》 SCIE 2024年第8期2426-2435,共10页
BACKGROUND Regarding when to treat gastric cancer and ovarian metastasis(GCOM)and whether to have metastatic resection surgery,there is presently debate on a global scale.The purpose of this research is to examine,in ... BACKGROUND Regarding when to treat gastric cancer and ovarian metastasis(GCOM)and whether to have metastatic resection surgery,there is presently debate on a global scale.The purpose of this research is to examine,in real-world patients with GCOM,the survival rates and efficacy of metastatic vs non-metastasized resection.AIM To investigate the survival time and efficacy of metastatic surgery and neoadjuvant therapy in patients with GCOM.METHODS This study retrospectively analyzed the data of 41 GCOM patients admitted to Zhejiang Provincial People’s Hospital from June 2009 to July 2023.The diagnosis of all patients was confirmed by pathology.The primary study endpoints included overall survival(OS),ovarian survival,OS after surgery(OSAS),disease-free survival(DFS),differences in efficacy.RESULTS This study had 41 patients in total.The surgical group(n=27)exhibited significantly longer median OS(mOS)and median overall months(mOM)compared to the nonoperative group(n=14)(mOS:23.0 vs 6.9 months,P=0.015;mOM:18.3 vs 3.8 months,P=0.001).However,there were no significant differences observed in mOS,mOM,median OSAS(mOSAS),and median DFS(mDFS)between patients in the surgical resection plus neoadjuvant therapy group(n=11)and those who surgical resection without neoadjuvant therapy group(n=16)(mOS:26.1 months vs 21.8 months,P=0.189;mOM:19.8 vs 15.2 months,P=0.424;mOSAS:13.9 vs 8.7 months,P=0.661,mDFS:5.1 vs 8.2 months,P=0.589).CONCLUSION Compared to the non-surgical group,the surgical group’s survival duration and efficacy are noticeably longer.The efficacy and survival time of the direct surgery group and the neoadjuvant therapy group did not differ significantly. 展开更多
关键词 Gastric cancer PROGNOSIS ovarian metastasis Neoadjuvant therapy SURGERY
下载PDF
Exploring the molecular mechanisms and potential therapeutic strategies of ferroptosis in ovarian cancer
2
作者 LISHA MA WANQI SHAO WEILI ZHU 《BIOCELL》 SCIE 2024年第3期379-386,共8页
The morbidity rate of ovarian cancer,a malignant tumour in gynaecological tumours,is rising,and it is considered to be the most lethal cancer.The majority of patients are typically diagnosed during the advanced stages... The morbidity rate of ovarian cancer,a malignant tumour in gynaecological tumours,is rising,and it is considered to be the most lethal cancer.The majority of patients are typically diagnosed during the advanced stages of the illness due to the elusive characteristics of ovarian cancer and an absence of highly sensitive and specific diagnostic indicators.Surgical excision of the lesions,along with chemotherapy,is the conventional treatment for ovarian cancer;however,resistance to platinum-based chemotherapeutic drugs and molecular targeted therapies frequently arises.Improving the survival rate and prognosis of patients with end-stage or recurring ovarian cancer requires the identification of new therapeutic targets due to the absence of efficient medications,and this has emerged as a highly demanding issue.Studies have demonstrated that ferroptosis effectively hinders the proliferation of ovarian cancer and induces the demise of malignant cells.Ferroptosis is composed of the cystine/glutamate antiporter system(the system Xc-)and glutathione peroxidase 4(GPX4).Solute carrier family 7 member 11(SLC7A11)and solute carrier family 3 member 2(SLC3A2)play crucial roles in the regulation of ferroptosis by facilitating the uptake of cystine into cells and the efflux of glutamate out of cells,respectively.In cells,GPX4 is the exclusive enzyme employed for reducing liposomal peroxide through glutathione peroxidase activity.The occurrence of ferroptosis in ovarian cancer is strongly associated with three main pathways,namely,the GPX4-glutathione(GSH)protective pathway,the ferroptosis suppressor protein 1(FSP1)-coenzyme Q10(CoQ10)protective pathway,and the guanosine 5'-triphosphate cyclohydrolase I(GCH1)protective pathway.In ovarian cancer cells,the postsynaptic density-95,discs-large,zona occludens 1(PDZ)-binding motif-angiopoietin-like 4-nicotinamide adenine dinucleotide phosphate oxidases 2(TAZ-ANGPTL4-NOX2)pathway can be regulated by Yes-associated protein(YAP)/TAZ,a downstream component of the Hippo pathway,leading to the modulation of ferroptosis.By targeting microRNA-587,lncRNA ADAMTS9 antisense RNA 1(ADAMTS9-AS1)can modulate the expression of SLC7A11 and reduce the occurrence of ferroptosis.Although ferroptosis holds promise in overcoming the resistance mechanism,there remain obstacles in utilizing it as a cancer treatment,including the potential harm of drugs to healthy cells.Hence,additional investigations are required to formulate safer and more efficient chemotherapy protocols for the treatment of ovarian cancer and other malignancies. 展开更多
关键词 ovarian cancer Ferroptosis therapy
下载PDF
Targeting endoplasmic reticulum stress signaling in ovarian cancer therapy
3
作者 Tianqing Yan Xiaolu Ma +1 位作者 Lin Guo Renquan Lu 《Cancer Biology & Medicine》 SCIE CAS CSCD 2023年第10期748-764,共17页
The endoplasmic reticulum(ER),an organelle present in various eukaryotic cells,is responsible for intracellular protein synthesis,post-translational modification,and folding and transport,as well as the regulation of ... The endoplasmic reticulum(ER),an organelle present in various eukaryotic cells,is responsible for intracellular protein synthesis,post-translational modification,and folding and transport,as well as the regulation of lipid and steroid metabolism and Ca2+homeostasis.Hypoxia,nutrient deficiency,and a low pH tumor microenvironment lead to the accumulation of misfolded or unfolded proteins in the ER,thus activating ER stress(ERS)and the unfolded protein response,and resulting in either restoration of cellular homeostasis or cell death.ERS plays a crucial role in cancer oncogenesis,progression,and response to therapies.This article reviews current studies relating ERS to ovarian cancer,the most lethal gynecologic malignancy among women globally,and discusses pharmacological agents and possible targets for therapeutic intervention. 展开更多
关键词 Endoplasmic reticulum stress unfolded protein response ovarian cancer targeted therapy
下载PDF
Ovarian cancer stem cells: Can targeted therapy lead to improved progression-free survival? 被引量:7
4
作者 Christen L Walters Haygood Rebecca C Arend +1 位作者 J Michael Straughn Donald J Buchsbaum 《World Journal of Stem Cells》 SCIE CAS 2014年第4期441-447,共7页
Despite significant effort and research funds, epithelial ovarian cancer remains a very deadly disease. There are no effective screening methods that discover early stage disease; the majority of patients are diagnose... Despite significant effort and research funds, epithelial ovarian cancer remains a very deadly disease. There are no effective screening methods that discover early stage disease; the majority of patients are diagnosed with advanced disease. Treatment modalities consist primarily of radical debulking surgery followed by taxane and platinum-based chemotherapy. Newer therapies including limited targeted agents and intraperitoneal delivery of chemotherapeutic drugs have improved disease-free intervals, but failed to yield longlasting cures in most patients. Chemotherapeutic resistance, particularly in the recurrent setting, plagues the disease. Targeting the pathways and mechanisms behind the development of chemoresistance in ovarian cancer could lead to significant improvement in patient outcomes. In many malignancies, including blood and other solid tumors, there is a subgroup of tumor cells, separate from the bulk population, called cancer stem cells(CSCs). These CSCs are thought to be the cause of metastasis, recurrence and resistance. However, todate, ovarian CSCs have been difficult to identify, isolate, and target. It is felt by many investigators that finding a putative ovarian CSC and a chemotherapeutic agent to target it could be the key to a cure for this deadly disease. This review will focus on recent advances in this arena and discuss some of the controversies surrounding the concept. 展开更多
关键词 EPITHELIAL ovarian cancer cancer stem cells CHEMORESISTANCE TARGETED therapy Chemotherapy RECURRENT ovarian cancer
下载PDF
Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action 被引量:14
5
作者 Hiroaki Itamochi 《World Journal of Biological Chemistry》 CAS 2010年第7期209-220,共12页
Ovarian cancer is the leading cause of death in women with gynecological cancer. Most patients are diagnosed at an advanced stage and have a poor prognosis.Currently, surgical tumor debulking, followed by platinum- an... Ovarian cancer is the leading cause of death in women with gynecological cancer. Most patients are diagnosed at an advanced stage and have a poor prognosis.Currently, surgical tumor debulking, followed by platinum- and taxane-based chemotherapy is the standard treatment for advanced ovarian cancer. However, these patients are at great risk of recurrence and emerging drug resistance. Therefore, novel treatment strategies are required to improve outcomes for women with advanced ovarian cancer. A variety of molecular targeted agents, the majority of which are monoclonal antibodies and small-molecule protein-kinase inhibitors, have been explored in the management of ovarian cancer. The targets of these agents include angiogenesis, the human epidermal growth factor receptor family, ubiquitinproteasome pathway, epigenetic modulators, poly(ADPribose) polymerase (PARP), and mammalian target of rapamycin (mTOR) signaling pathway, which are aberrant in tumor tissue. The antiangiogenic agent, bevacizumab, has been reported as the most effective targeted agent and should be included in the standard chemotherapeutic regimen for advanced ovarian cancer. PARP inhibitors, which are mainly used in breast and ovarian cancer susceptibility gene-mutated patients, and mTOR inhibitors are also attractive treatment strategies, either alone or combination with chemotherapy, for ovarian cancer. Understanding the tumor molecular biology and identification of predictive biomarkers are essential steps for selection of the best treatment strategies. This article reviews the molecular mechanisms of the most promising targeted agents that are under early phase clinical evaluation for ovarian cancer. 展开更多
关键词 TARGETED therapy EPITHELIAL ovarian cancer Molecular target MONOCLONAL ANTIBODY SMALL-MOLECULE inhibitor
下载PDF
Recurrent epithelial ovarian cancer and hormone therapy
6
作者 Yoshihito Yokoyama Hideki Mizunuma 《World Journal of Clinical Cases》 SCIE 2013年第6期187-190,共4页
The role of hormone therapy in the treatment of ovarian cancer is not clear. Data on the efficacy and safety of antiestrogens and aromatase inhibitors in recurrent ovarian cancer have been accumulated through phase Ⅱ... The role of hormone therapy in the treatment of ovarian cancer is not clear. Data on the efficacy and safety of antiestrogens and aromatase inhibitors in recurrent ovarian cancer have been accumulated through phase Ⅱ clinical studies. Most of these studies were conducted in platinum-resistant recurrent ovarian cancer, and although complete response rates were not high, reported adverse events were low. If administered to patients who are positive for estrogen receptors, hormone therapy may become a viable option for the treatment of recurrent ovarian cancer. 展开更多
关键词 Recurrent ovarian cancer HORMONE therapy LETROZOLE ANASTROZOLE TAMOXIFEN FULVESTRANT
下载PDF
Current Possible Drug Therapies for Ovarian Cancer
7
作者 Jungyeob Seoung Young-Han Park +1 位作者 Chaechun Rhim Sungju Kim 《Journal of Cancer Therapy》 2014年第13期1203-1214,共12页
Ovarian cancer is the most aggressive gynecologic cancer of the heterogenous phenotypes. Development of the new chemotherapeutic agents and drug delivery mode makes better outcomes for patient treatments. Optimal cyto... Ovarian cancer is the most aggressive gynecologic cancer of the heterogenous phenotypes. Development of the new chemotherapeutic agents and drug delivery mode makes better outcomes for patient treatments. Optimal cytoreductive therapy followed by molecular targeting therapy, intraperitoneal chemotherapy and dose dense chemotherapy is a hot therapeutic concept in ovarian cancers. In our review, we will introduce recent therapeutic advances in epithelial ovarian cancer patients. 展开更多
关键词 ovarian cancer INTRAPERITONEAL CHEMOtherapy TARGETING therapy
下载PDF
The Administration of Ocoxin Increases the Quality of Life of Patients with Advanced Epithelial or Metastatic Ovarian Cancer Undergoing Neoadjuvant Chemotherapy
8
作者 Karen López Miguel Daniel Ricardo Martínez Ávila +20 位作者 Lliset Álvarez Pérez Gisselle Martínez Rabasa Alejandro Linchenat Lambert Roberto Esperón Noa Lisandra Heredia Manzano Margarita De Quesada Amigó Rafael I. Reyes Velázquez Danay Corrales Otero Ramon Ropero Toirac Idelmis Curbelo Heredia Mircea Betancourt Cabeza Tania A. Agrelo Ramos Rosa María Muñoz Reyes Juan Jesús Lence Anta Rosalía Fuentes Sosa Karelia Silvera Candó Kirenia Silva Rodríguez Zaida Lastre Sosa Mayte Robaina García Eduardo Sanz David Marquez 《Journal of Cancer Therapy》 CAS 2022年第9期561-584,共24页
Background: 70% of ovarian cancer cases are diagnosed at an advanced stage (III or IV) of the disease and, in turn, with a high prevalence of peritoneal carcinosis and ascites, which leads to progressive malnutrition ... Background: 70% of ovarian cancer cases are diagnosed at an advanced stage (III or IV) of the disease and, in turn, with a high prevalence of peritoneal carcinosis and ascites, which leads to progressive malnutrition in patients, with the consequent deterioration of their general condition. There is a very important relationship between nutritional status, quality of life, survival, and the ability to tolerate multidisciplinary treatment of peritoneal carcinosis. Methods: A phase II, open-label, single-center, non-randomised clinical trial was conducted that included 36 patients with advanced disease who were administered the nutritional supplement Ocoxin, 30 ml twice a day, beginning one week before chemotherapy (CT) based on carboplatin/paclitaxel, of which they receive three cycles with neoadjuvant intent. Ocoxin treatment was continued during chemotherapy and for three weeks after completion of the last cycle, as well as during any periods for which this treatment was discontinued due to toxicity. The effect of Ocoxin on the quality of life was assessed through the QLQ C30 and QLQ OV28 questionnaires from the start of treatment until the end of the follow-up period. In addition, the Karnofsky Index and nutritional parameters were assessed. Results: There were no significant differences between adverse events versus baseline values, except in leukocytes, lymphocytes, neutrophils, ALT, and AST. There was no deterioration of the QoL scales, except for those related to the effects of chemotherapy and alopecia. Conclusions: Ocoxin as an adjuvant to chemotherapy appears to improve better tolerance to chemotherapy, showed a good safety profile, and improved quality of life. For further information on Ocoxin neoadjuvant therapy benefits, a phase III clinical trial will be needed. 展开更多
关键词 Chemotherapy Radiotherapy ovarian cancer ONCOLOGY Quality of Life Ad-juvant therapy Supportive Care
下载PDF
Potential of vesicular stomatitis virus as an oncolytic therapy for recurrent and drug-resistant ovarian cancer
9
作者 Joshua F. Heiber Glen N. Barber 《Chinese Journal of Cancer》 SCIE CAS CSCD 北大核心 2011年第12期805-814,共10页
In the last decade, we have gained significant understanding of the mechanism by which vesicular stomatitis virus (VSV) specifically kills cancer cells. Dysregulation of translation and defective innate immunity are b... In the last decade, we have gained significant understanding of the mechanism by which vesicular stomatitis virus (VSV) specifically kills cancer cells. Dysregulation of translation and defective innate immunity are both thought to contribute to VSV oncolysis. Safety and efficacy are important objectives to consider in evaluating VSV as a therapy for malignant disease. Ongoing efforts may enable VSV virotherapy to be considered in the near future to treat drug-resistant ovarian cancer when other options have been exhausted. In this article, we review the development of VSV as a potential therapeutic approach for recurrent or drug-resistant ovarian cancer. 展开更多
关键词 水泡性口炎病毒 卵巢癌 耐药性 治疗 VSV 免疫缺陷 癌细胞 安全性
下载PDF
Recent advances in targeted therapy for ovarian cancer
10
作者 Tianyu Qin Gang Chen 《Oncology and Translational Medicine》 CAS 2022年第1期28-35,共8页
The global burden of ovarian cancer is gradually increasing while patients still suffer from relatively limited treatment options.With recent advances in the decoding of the molecular landscape of ovarian cancer,more ... The global burden of ovarian cancer is gradually increasing while patients still suffer from relatively limited treatment options.With recent advances in the decoding of the molecular landscape of ovarian cancer,more options in targeted strategy were offered and can therefore be tailored in different clinical settings for individual patient.Targeting of the abnormal angiogenesis process is the first significant clinical breakthrough which revolutionized the treatment of advanced ovarian cancer,followed by the advent of poly-(ADP)-ribose polymerase(PARP)inhibitors.These two strategies represented by bevacizumab and olaparib respectively underwent tests of numerous clinical trials.In recent years,immune checkpoint inhibitors(ICIs)have been incorporated into the blueprint of ovarian cancer treatment though the effectiveness still left much to be desired.Herein,we systematically outlined recent advances in targeted therapy for ovarian cancer and summarized the landmark clinical trials for each targeted therapy including angiogenesis inhibitors,PARP inhibitors and ICIs. 展开更多
关键词 ovarian cancer targeted therapy ANTI-ANGIOGENESIS poly-(ADP)-ribose polymerase(PARP)inhibitor immune checkpoint inhibitor(ICI) clinical trial
下载PDF
Research Progress of Nectin-4 as a Targeted Therapy for Ovarian Cancer
11
作者 Xinmeng Wang Jinzhi Lu Cunjian Yi 《Yangtze Medicine》 2022年第4期114-120,共7页
Ovarian cancer is one of the most common gynecological malignancies. The 5-year survival rate of ovarian cancer is only 50%, which is considered to be the most lethal gynecologic malignant tumor.The high mortality of ... Ovarian cancer is one of the most common gynecological malignancies. The 5-year survival rate of ovarian cancer is only 50%, which is considered to be the most lethal gynecologic malignant tumor.The high mortality of ovarian cancer patients can be attributed to chemotherapy resistance, extensive intraperitoneal metastasis and other factors.Tumor antigens are expressed on the surface of tumor cells and represent potential drug targets.One of the antigens is tumor associated nectin-4, which is a member of the immune globulin superfamily.This review highlights the role of nectin-4 as a therapeutic target for ovarian cancer, and discusses the relevant research data, which is an effective new direction in the treatment of ovarian cancer.Although there are still some challenges, targeted therapy is still a promising treatment for ovarian cancer. 展开更多
关键词 ovarian cancer Nectin-4 Antibody Drug Conjugate (ADC) Targeted therapy
下载PDF
COX-2 blocking therapy in cisplatin chemosensitization of ovarian cancer:An allicin-based nanomedicine approach
12
作者 Huijiao Fu Peiqin Liang +8 位作者 Qianwen Chen Yan Wang Guang Li Xuzi Cai Shengtao Wang Kun Chen Shengying Shi Zhiqiang Yu Xuefeng Wang 《Chinese Chemical Letters》 SCIE CAS CSCD 2024年第8期449-454,共6页
Recently,the utilization of nonsteroidal anti-inflammatory drugs(NSAIDs)to sensitize cisplatin(CDDP)has gained substantial traction in the treatment of ovarian cancer(OC).However,even widely employed NSAIDs such as ce... Recently,the utilization of nonsteroidal anti-inflammatory drugs(NSAIDs)to sensitize cisplatin(CDDP)has gained substantial traction in the treatment of ovarian cancer(OC).However,even widely employed NSAIDs such as celecoxib and naproxen carry an elevated risk of cardiovascular events,notably throm-bosis.Furthermore,the diminished sensitivity to CDDP therapy in OC is multifactorial,rendering the ap-plication of NSAIDs only partially effective due to their cyclooxygenase-2(COX-2)inhibiting mechanism.Hence,in this study,reactive oxygen species(ROS)-responsive composite nano-hydrangeas loaded with the Chinese medicine small molecule allicin and platinum(IV)prodrug(DTP@AP NPs)were prepared to achieve comprehensive chemosensitization.On one front,allicin achieved COX-2 blocking therapy,en-compassing the inhibition of proliferation,angiogenesis and endothelial mesenchymal transition(EMT),thereby mitigating the adverse impacts of CDDP chemotherapy.Simultaneously,synergistic chemosensi-tization was achieved from multifaceted mechanisms by decreasing CDDP inactivation,damaging mito-chondria and inhibiting DNA repair.In essence,these findings provided an optimized approach for syner-gizing CDDP with COX-2 inhibitors,offering a promising avenue for enhancing OC treatment outcomes. 展开更多
关键词 COX-2 blocking therapy CDDP CHEMOSENSITIZATION ALLICIN ovarian cancer
原文传递
Aiming to immune elimination of ovarian cancer stem cells 被引量:8
13
作者 Jiabo Di Tjitske Duiveman-de Boer +1 位作者 Carl G Figdor Ruurd Torensma 《World Journal of Stem Cells》 SCIE CAS 2013年第4期149-162,共14页
Ovarian cancer accounts for only 3% of all cancers in women, but it causes more deaths than any other gynecologic cancer. Treatment with chemotherapy and cytoreductive surgery shows a good response to the therapy. How... Ovarian cancer accounts for only 3% of all cancers in women, but it causes more deaths than any other gynecologic cancer. Treatment with chemotherapy and cytoreductive surgery shows a good response to the therapy. However, in a large proportion of the patients the tumor grows back within a few years. Cancer stem cells, that are less responsive to these treatments, are blamed for this recurrence of disease. Immune therapy either cellular or humoral is a novel concept to treat cancer. It is based on the notice that immune cells invade the tumor. However, the tumor invest heavily to escape from immune elimination by recruiting several immune suppressive mechanisms. These processes are normally in place to limit excessive immune activation and prevent autoimmune phenomena. Here, we discuss current knowledge about the immune(suppressive)status in ovarian cancer. Moreover, we discuss the immunological targets of ovarian cancer stem cells. 展开更多
关键词 ovarian cancer cancer stem cell IMMUNE therapy IMMUNE suppression TUMOR MICROENVIRONMENT
下载PDF
Hedgehog signaling pathway and ovarian cancer 被引量:9
14
作者 Qi Chen Guolan Gao Shiwen Luo 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2013年第3期346-353,共8页
Epithelial ovarian carcinoma (EOC) is the most common form of ovarian malignancies and the most lethal gynecologic malignancy in the United States. To date, in spite of treatment to it with the extensive surgical de... Epithelial ovarian carcinoma (EOC) is the most common form of ovarian malignancies and the most lethal gynecologic malignancy in the United States. To date, in spite of treatment to it with the extensive surgical debulking and chemotherapy, the prognosis of EOC remains dismal. Recently, it has become increasingly clear that in many instances, the signaling and molecular players that control development are the same, and when inappropriately regulated, drive tumorigenesis and cancer development. Here, we discuss the possible involvement of Hedgehog (Hh) pathway in the cellular regulation and development of cancer in the ovaries. Using the in vitro and in vivo assays developed has facilitated the dissection of the mechanisms behind Hh-driven ovarian cancers formation and growth. Based on recent studies, we propose that the inhibition of Hh signaling may interfere with spheroid-like structures in ovarian cancers. The components of the Hh signaling may provide novel drug targets, which could be explored as crucial combinatorial strategies for the treatment of ovarian cancers. 展开更多
关键词 Hedgehog signaling ovarian cancer targeted therapy
下载PDF
Ovarian cancer:a molecularly insidious disease 被引量:8
15
作者 Delia Mezzanzanica 《Chinese Journal of Cancer》 SCIE CAS CSCD 2015年第1期1-3,共3页
In this issue of the Chinese Journal of Cancer,European,American,and Chinese experts review the current management and future perspectives of epithelial ovarian cancer(EOC),the leading cause of gynecological cancer de... In this issue of the Chinese Journal of Cancer,European,American,and Chinese experts review the current management and future perspectives of epithelial ovarian cancer(EOC),the leading cause of gynecological cancer deaths.Although major advances have been made in understanding the cellular and molecular biology of this highly heterogeneous malignancy,the survival rate of women with EOC has changed little since the introduction of platinum-based treatment as a front-line therapy.The papers describe the progress in deciphering the molecular complexity of this disease and the newly available molecular-driven therapies,which have been applied by shifting trial designs toward restricting eligibility to specific subgroups of patients rather than testing agents in unselected populations.These new trial designs provide potential opportunities for improved efficacy in targeted populations.Given the molecular complexity of this disease,patient survival may be increased by searching for new molecular prognostic/predictive signatures as well as by translating the recent insight of microRNA involvement in EOC progression into new,targeted therapies.Particular attention has been given to the issue of fertility sparing for women affected by curable diseases. 展开更多
关键词 分子生物学 卵巢癌 疾病 靶向治疗 试验设计 EOC 微RNA 复杂性
下载PDF
Effects of multiple tumor suppressor 1 on the proliferation of human ovarian cancer HO-8910 cells
16
作者 刘淑娟 辛晓燕 +2 位作者 韩军涛 汤朝武 王德堂 《Journal of Medical Colleges of PLA(China)》 CAS 1999年第3期232-234,共3页
objective: To investigate the effects of multiple tumor suppressor 1 on the proliferation of ovarian cancer cell lines. Methods: Growth characteristics of HO-8910 (without p16 gene expression ), 8910-p16 (trans fected... objective: To investigate the effects of multiple tumor suppressor 1 on the proliferation of ovarian cancer cell lines. Methods: Growth characteristics of HO-8910 (without p16 gene expression ), 8910-p16 (trans fected with p16 gene) and 8910-pcDNA3 (transfected with the vector pcDNA3) cells were studied by comparison of the cell growth curves. DNA synthesis was also compared among the 3 kinds of cells. Results: After trans fected with p16 gene, the 8910-p16 cells were markedly inhibited in both the proliferation and DNA synthesis. There was no significant difference between the 8910-pcDNA3 cells and the HO-8910 cells. Conclusion: Multiple tumor suppressor 1 can inhibit the proliferation and DNA synthesis of human ovarian cancer HO-8910 cells. 展开更多
关键词 ovarian cancer MULTIPLE TUMOR SUPPRESSOR 1 gene therapy
下载PDF
Influence of Deleted in Colorectal Carcinoma Gene on Proliferation of Ovarian Cancer Cell Line SKOV-3 In Vivo and In Vitro
17
作者 Yan Cai Chun-jie Hu +1 位作者 Jia Wang Ze-hua Wang 《Chinese Medical Sciences Journal》 CAS CSCD 2011年第3期175-181,共7页
Objective To elucidate the effects of the deleted in colorectal carcinoma(DCC) gene on proliferation of ovarian cancer cell line SKOV-3.Method An exogenous recombinant eukaryotic expression vector pcDNA3.1(+)-DCC,cont... Objective To elucidate the effects of the deleted in colorectal carcinoma(DCC) gene on proliferation of ovarian cancer cell line SKOV-3.Method An exogenous recombinant eukaryotic expression vector pcDNA3.1(+)-DCC,containing human DCC cDNA coding sequences,was constructed and transfected into SKOV-3 cells(SKOV-3/DCC).The pcDNA3.1(+) transfected cells(SKOV-3/Neo) and SKOV-3 cells were used as the positive and negative controls,respectively.Expressions of DCC mRNA and protein were analyzed by RT-PCR and immunocytochemical analysis,respectively.Cell growth was detected by soft agar colony formation assay and MTT assay.Flow cytometry and transmission electron microscopy were used to assess the effects of DCC on cell cycle distribution and ultrastructure,respectively.BALB/c mice were used to evaluate the effects of DCC on tumorigenicity in vivo.Results RT-PCR and immunocytochemical analysis revealed the exogenous DCC gene was successfully transfected into SKOV-3 cell lines and obtained permanent expression.The half maximal inhibitory concentration(IC50) of SKOV-3/DCC cells was significantly lower than that of SKOV-3 or SKOV-3/Neo cells(all P<0.05).DCC expression caused SKOV-3 cells to be arrested in G1 phase(78.0%),and electron microscopic analysis showed SKOV-3/DCC cells displayed typical morphological changes of apoptosis.Two mice xenografted with SKOV-3/DCC cells showed no tumor tumorigenecity.The tumor volume of BALB/c mice bearing SKOV-3/DCC cells(3.403 mm3) was smaller than that of SKOV-3 cells(9.206 mm3).Conclusion DCC gene may play an important role in suppressing the growth of SKOV-3 cell line and inducing apoptosis. 展开更多
关键词 ovarian cancer deleted in colorectal carcinoma gene gene therapy
下载PDF
Non-viral targeted delivery system mediates transfection of thymidine kinase gene of herpes simplex virus into ovarian cancer cells:a comparison between one time and continuous mediation
18
作者 Xiaojun Liu Zhijun Jin +4 位作者 Kangyun Xie Xiaoxi Huo Xinyan Zhang Yan Liu Congjian Xu 《The Chinese-German Journal of Clinical Oncology》 CAS 2008年第6期368-371,共4页
Objective: To compare the transferring efficiency and killing effects of one time and continuous mediation with GE7, a non-viral targeted delivery system, in transfection of thymidine kinase gene of herpes simplex vi... Objective: To compare the transferring efficiency and killing effects of one time and continuous mediation with GE7, a non-viral targeted delivery system, in transfection of thymidine kinase gene of herpes simplex virus (HSV-tk) into ovarian cancer cells. Methods: GE7 was used to prepare recombinants with β-galactosidase (β-gal) and HSVI-tk; the recombinants were then used to transfect human ovarian cancer line CaOV3 once and continuously. β-gal staining was used to compare the efficiencies of one time and continuous mediation with GE7 system. Ganciclovior (GCV) was introduced into HSVI-tk transfected ovarian cells. Through drawing the cell growth curve and flow cytometry, the killing effects of GCV on once and continuously GE7/HSVI-tk transfected cells were observed. Results: We found that the one time and continuous exogenous gene transfer efficiencies were about 80% and 85%, respectively. When 1 μg/mL GCV was used to treat ovarian cell transfected with HSVI-tk gene, growth inhibiting rates of ovarian cells of one time and continuous transferring were 82% and 90%, respectively; their apoptosis indices were 15 and 30, respectively. Under same GCV concentration, continuous mediation of GE7/pCMV-tk transfection into ovarian cancer cells had more significant inhibitory effect than one time mediation (P 〈 0.05). Conclusion: Compared with one time mediation, continuous mediation of transfection with GE7 gene delivery system has higher efficiency. Continuous mediation of GE7/HSVI-tk/GCV therapeutic gene system has more powerful killing effect. 展开更多
关键词 ovarian cancer gene therapy targeted non-viral vector
下载PDF
Advances in precision treatment of ovarian cancer
19
作者 Xiao-Dong Wang Jin-Feng Liu 《Precision Medicine Research》 2020年第1期26-32,共7页
Ovarian cancer is one of the most common malignant tumors in female reproductive organs.Due to the lack of effective screening and early diagnosis methods,the vast majority of patients with ovarian cancer are in advan... Ovarian cancer is one of the most common malignant tumors in female reproductive organs.Due to the lack of effective screening and early diagnosis methods,the vast majority of patients with ovarian cancer are in advanced stages once diagnosed.Precision therapy mainly includes immunotherapy,targeted therapy,biological therapy,and gene therapy.At present,precision therapy is increasingly used in the clinical treatment of ovarian cancer due to its advantages,such as fewer side effects and a high degree of killing.This article summarizes the recent advances in the precise treatment of ovarian cancer. 展开更多
关键词 ovarian cancer Precision therapy IMMUNOtherapy Targeted therapy Biological therapy Gene therapy
下载PDF
Alpha1B adrenoceptor expression is a marker of reduced survival and increased tumor recurrence in patients with endometrioid ovarian cancer
20
作者 Dascha Deutsch Suha Deen +4 位作者 Frank Entschladen Clare Coveney Robert Rees Kurt S Zanker Desmond George Powe 《World Journal of Obstetrics and Gynecology》 2016年第1期118-126,共9页
AIM: To investigate the expression patterns of different adrenoceptor isoforms in ovarian cancer and their association with survival and tumor recurrence. METHODS: The protein expression levels of a1 B, a2 C and b2 ad... AIM: To investigate the expression patterns of different adrenoceptor isoforms in ovarian cancer and their association with survival and tumor recurrence. METHODS: The protein expression levels of a1 B, a2 C and b2 adrenoceptor were assessed in unselected ovarian cancer using immunohistochemistry on microarrayed archival tissue samples. A database containing clinical and pathology parameters and follow-up was usedto investigate the association between adrenoceptor isoform expression with ovarian specific survival and tumor recurrence, using univariate and multivariate statistical analysis. RESULTS: Expression of a1 B showed an association with reduced ovarian specific survival(P = 0.05; CI: 1.00-1.49) and increased tumor recurrence(P = 0.021, CI: 1.04-1.69) in the whole patient group. On subanalysis the expression of a1 B in endometrioid cancers(χ2 = 5.867, P = 0.015) was found to predict reduced ovarian specific survival and increased tumor recurrence independently of tumor grade, clinical stage and chemotherapy. An association with clinical outcome was not seen for a2 C or b2 AR.CONCLUSION: Alpha1 B adrenoceptor protein was found to predict increased risk of tumor recurrence and reduced mortality in patients with endometrioid type ovarian cancer and should be investigated as a biomarker for identifying patients at increased risk of disease progression. Furthermore, a adrenergic receptor antagonists with a1 B selectivity should be investigated as a possible adjuvant therapy for treating patients with endometrioid cancer. Proof of principle could be tested in a retrospective population study. 展开更多
关键词 Alpha adrenoceptor Beta adrenoceptor b-blockers a-blockers ovarian cancer Prognosis cancer therapy
下载PDF
上一页 1 2 19 下一页 到第
使用帮助 返回顶部